Estrella Immunopharma, Inc. (ESLA) vs NextCure, Inc. (NXTC)
A side-by-side comparison of Estrella Immunopharma, Inc. and NextCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ESLA
Estrella Immunopharma, Inc.
$0.41HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
NXTC
NextCure, Inc.
$5.25HealthcareDelayed quote: Oct 6, 2026, 12:42 PM EDT
Total return — ESLA vs NXTC
growth of $100 · dividends reinvested · last 5yESLA -95.5% (-46.2%/yr)NXTC -94.3% (-43.6%/yr)NXTC compounded faster over this window
ESLA NXTC
ESLA vs NXTC: by the numbers
- •NXTC is the larger company ($19M vs $18M market cap).
Metrics side by side
Valuation
| Metric | ESLA | NXTC |
|---|---|---|
| P/B ratio | N/A | 1.56 |
Profitability
| Metric | ESLA | NXTC |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | N/A | -351.86% |
| ROIC | N/A | -259.91% |
Growth (annualized)
| Metric | ESLA | NXTC |
|---|---|---|
| Total return CAGR (5Y) | -46.34% | -44.29% |
Frequently asked
- How have ESLA and NXTC total returns compared?
- Over the past 5 years, ESLA delivered -46.34% and NXTC delivered -44.29% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.